Summit Therapeutics Inc.
SMMT
Peringkat dalam Saham
#1658
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Harga Saham
$16.14
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$12.87B
Perubahan (1 hari)
3.65%
Perubahan (1 tahun)
-13.88%
Negara
US
Perdagangan Summit Therapeutics Inc. (SMMT)
Kategori
Healthcare
Rasio P/E untuk Summit Therapeutics Inc. (SMMT)
Rasio P/E per October 2026 TTM: -13.51
Menurut laporan keuangan dan harga saham terbaru dari Summit Therapeutics Inc., rasio P/E saat ini (TTM) adalah -13.51. Pada akhir 2023, perusahaan memiliki rasio P/E sebesar -2.63.
Riwayat rasio P/E untuk Summit Therapeutics Inc. dari 2004 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | -13.51 | -76.69% |
| 2024 | -57.95 | 2,103.56% |
| 2023 | -2.63 | -74.78% |
| 2022 | -10.43 | 272.44% |
| 2021 | -2.80 | -54.84% |
| 2020 | -6.20 | 275.10% |
| 2019 | -1.65 | -92.50% |
| 2018 | -22.05 | -8.03% |
| 2017 | -23.97 | 54.35% |
| 2016 | -15.53 | -0.75% |
| 2015 | -15.65 | -13.69% |
| 2014 | -18.13 | 19.12% |
| 2013 | -15.22 | -14.32% |
| 2012 | -17.76 | -45.72% |
| 2011 | -32.72 | -33.78% |
| 2010 | -49.42 | 325.86% |
| 2009 | -11.60 | -4.85% |
| 2008 | -12.20 | -61.72% |
| 2007 | -31.86 | -66.31% |
| 2006 | -94.56 | -93.55% |
| 2005 | -1.47K | -42.13% |
| 2004 | -2.53K | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 28.78 | -313.06% |
US
|
|
| -28.36 | 109.92% |
US
|
|
| -24.57 | 81.86% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -324.52% |
NL
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.